Japanese Kyowa's Antibody Technology Could Mean Cheaper Development Costs For Amgen - Analysts
This article was originally published in PharmAsia News
Executive Summary
TOKYO - The size of the up-front payment that Amgen provided Kyowa Hakko Kogyo this week to gain development and commercialization rights to the Phase I humanized monoclonal antibody KW-0761 for most of the world - except Japan, Korea, China and Taiwan - indicates strong interest in the Japanese company's Potelligent technology, experts say
You may also be interested in...
Kyowa Hakko Kirin Pins Rebound On KW-0761 For Oncology And Allergy Indications
TOKYO - Kyowa Hakko Kirin posted modest gains in its pharmaceutical business at its announcement of interim results as expectation rides on the eventual outcome of KW-0761, a humanized anti-CCR-4 monoclonal antibody being developed by Kyowa for hematological cancer applications in Japan and the U.S. and by licensing partner Amgen in the U.K. for allergy application
Kyowa Hakko Kirin Pins Rebound On KW-0761 For Oncology And Allergy Indications
TOKYO - Kyowa Hakko Kirin posted modest gains in its pharmaceutical business at its announcement of interim results as expectation rides on the eventual outcome of KW-0761, a humanized anti-CCR-4 monoclonal antibody being developed by Kyowa for hematological cancer applications in Japan and the U.S. and by licensing partner Amgen in the U.K. for allergy application
Kyowa Hakko Kirin Pledges To Become Japan’s Top Biotech-based Pharma – Bio Japan
YOKOHAMA, Japan - Yuzuru Matsuda, president and CEO of Kyowa Hakko Kirin Co., said his company aimed to become "the top-class global biotechnology-based pharma that does research and development in the area of life sciences out of Japan, continuously making innovative contributions with antibody drugs." Matsuda spoke to an audience at Bio Japan in Yokohama Oct. 17